Sofinnova Investments, a clinical stage biopharmaceutical investment firm, has named Maha Katabi, PhD as the new partner in its investment team, it was reported yesterday.

Dr Katabi is an experienced investor in biopharma companies, with more than 18 years in venture capital investing and public equities portfolio management. Prior to founding Oxalis in 2018, Dr Katabi was a partner at Sectoral Asset Management since 2008, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. Additionally, she was a portfolio manager for a family of funds that invested in publicly listed and private healthcare companies. Prior to Sectoral, Maha was vice-president at Ventures West Management, a venture capital firm focused on technology and life sciences in Canada and the United States. She started her venture capital career in 1999 at T2C2 Capital Bio, a seed fund targeting Canadian start-ups.

Jim Healy, MD, PhD, and general partner of Sofinnova, said, 'We believe Maha is an exceptional investor with a track record of successful public offerings and acquisitions. We are fortunate to have her join our team. Her experience will contribute a seasoned perspective which we deem will add tremendous value in expanding our investing capabilities.'